Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines
Sign Up to like & getrecommendations! Published in 2020 at "Human Mutation"
DOI: 10.1002/humu.24060
Abstract: Early onset breast cancer is the most common malignancy in women with Li‐Fraumeni syndrome, caused by germline TP53 pathogenic variants. It has repeatedly been suggested that breast tumors from TP53 carriers are more likely to… read more here.
Keywords: her2 breast; breast; breast tumor; pathology ... See more keywords
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-018-4751-9
Abstract: PurposeG protein-coupled receptors (GPCRs) represent the largest family of druggable targets in human genome. Although several GPCRs can cross-talk with the human epidermal growth factor receptors (HERs), the expression and function of most GPCRs remain… read more here.
Keywords: her2; breast cancer; gpcrs; her2 breast ... See more keywords
NRF1 motif sequence-enriched genes involved in ER/PR −ve HER2 +ve breast cancer signaling pathways
Sign Up to like & getrecommendations! Published in 2018 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-018-4905-9
Abstract: Nuclear respiratory factor 1 (NRF1) transcription factor has recently been shown to control breast cancer progression. However, mechanistic aspects by which NRF1 may contribute to susceptibility to different breast tumor subtypes are still not fully… read more here.
Keywords: her2 breast; breast; breast cancer; nrf1 motif ... See more keywords
The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2- breast cancer and is associated with inferior outcomes.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of geriatric oncology"
DOI: 10.1016/j.jgo.2020.08.007
Abstract: OBJECTIVES To establish whether clinicopathologic and genomic characteristics may explain the poor prognosis associated with advanced age in ER+/HER2- breast cancer. MATERIALS AND METHODS The cohort included 271 consecutive post-menopausal patients with ER+/HER2- invasive breast… read more here.
Keywords: older patients; breast cancer; her2 breast; luminal subtype ... See more keywords
Melatonin potentiates the cytotoxic effect of Neratinib in HER2+ breast cancer through promoting endocytosis and lysosomal degradation of HER2
Sign Up to like & getrecommendations! Published in 2021 at "Oncogene"
DOI: 10.1038/s41388-021-02015-w
Abstract: Complete blockade of the HER2 protein itself and HER signaling network is critical to achieving effective HER2-targeted therapies. Despite the success of HER2-targeted therapies, the diseases will relapse in a significant fraction of patients with… read more here.
Keywords: her2 breast; breast cancer; effect; melatonin ... See more keywords
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Sign Up to like & getrecommendations! Published in 2020 at "NPJ Breast Cancer"
DOI: 10.1038/s41523-020-0153-3
Abstract: Human epidermal growth factor receptor 2–positive (HER2+) breast cancer accounts for ~25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to unparalleled clinical benefit for a subset of patients with HER2+ breast… read more here.
Keywords: cancer; immunotherapies her2; her2 breast; breast cancer ... See more keywords
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-90385-2
Abstract: HER2-positive (HER2 +) breast cancer patients that do not respond to targeted treatment have a poor prognosis. The effects of targeted treatment on endogenous microRNA (miRNA) expression levels are unclear. We report that responsive HER2 + breast cancer… read more here.
Keywords: her2 breast; mir; breast; breast cancer ... See more keywords
Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-96351-2
Abstract: Prognosis of patients with HER2+ breast-to-brain-metastasis (BBM) is dismal even after current standard-of-care treatments, including surgical resection, whole-brain radiation, and systemic chemotherapy. Radiation and systemic chemotherapies can also induce cytotoxicity, leading to significant side effects. Studies… read more here.
Keywords: her2 breast; hipsc platelets; human induced; induced pluripotent ... See more keywords
Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles
Sign Up to like & getrecommendations! Published in 2022 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2205454119
Abstract: Significance This study demonstrates the therapeutic efficacy of ceramide-conjugated nanoparticles (PPP-CNP) in trastuzumab-resistant human epidermal growth factor receptor 2-positive (HER2+) breast cancer. The shedding/loss of the HER2 extracellular domain plays a significant role in trastuzumab… read more here.
Keywords: breast cancer; her2; ceramide; her2 breast ... See more keywords
Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Disease Markers"
DOI: 10.1155/2020/6103542
Abstract: Aerobic glycolysis is a hallmark of tumor cells. SGLT1 plays a vital role in glucose metabolism. However, whether SGLT1 could promote cell growth and proliferation in breast cancer remains unclear. Here, we investigated the expression… read more here.
Keywords: her2 breast; breast cancer; cancer; sglt1 ... See more keywords
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-1131
Abstract: Purpose: The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater in… read more here.
Keywords: neratinib; her2 breast; adjuvant therapy; extended adjuvant ... See more keywords